Portfolio Holdings Detail for ISIN IE00BYXG2H39
| Stock Name / Fund | iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares IV Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300ZP07LMR36K1T02 |
| ETF Ticker | BTEC(USD) LSE |
| ETF Ticker | BTEK(GBP) LSE |
| ETF Ticker | 2B70(EUR) F |
| ETF Ticker | 2B70.DE(EUR) CXE |
| ETF Ticker | BTEC.LS(USD) CXE |
| ETF Ticker | BTEK.LS(GBP) CXE |
| ETF Ticker | BTEC.L(GBP) LSE |
| ETF Ticker | BTEK.L(GBP) LSE |
Holdings detail for RGNX
| Stock Name | Regenxbio Inc |
| Ticker | RGNX(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US75901B1070 |
| LEI | 549300EOES47LATSET33 |
Show aggregate RGNX holdings
News associated with RGNX
- REGENXBIO Inc. (NASDAQ:RGNX) Receives $28.38 Consensus PT from Analysts
- REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) has been given an average recommendation of “Moderate Buy” by the six analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price objective […] - 2025-09-16 03:06:58
- REGENXBIO (NASDAQ:RGNX) Receives Buy Rating from HC Wainwright
- REGENXBIO (NASDAQ:RGNX – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They presently have a $34.00 target price on the biotechnology company’s stock. HC Wainwright’s price target suggests a potential upside of 243.78% from the stock’s current price. […] - 2025-09-10 03:00:56
- REGENXBIO (NASDAQ:RGNX) Earns Buy Rating from Chardan Capital
- Chardan Capital restated their buy rating on shares of REGENXBIO (NASDAQ:RGNX – Free Report) in a report released on Monday,Benzinga reports. They currently have a $52.00 target price on the biotechnology company’s stock. Several other analysts have also recently issued reports on RGNX. Royal Bank Of Canada lowered their price objective on shares of REGENXBIO […] - 2025-09-09 03:10:46
- Mitsubishi UFJ Asset Management Co. Ltd. Boosts Holdings in REGENXBIO Inc. (NASDAQ:RGNX)
- Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 9.1% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 27,756 shares of the biotechnology company’s stock after purchasing an additional 2,326 shares during the period. […] - 2025-08-15 04:47:03
- REGENXBIO (NASDAQ:RGNX) Price Target Lowered to $17.00 at Royal Bank Of Canada
- REGENXBIO (NASDAQ:RGNX – Free Report) had its target price trimmed by Royal Bank Of Canada from $21.00 to $17.00 in a research report sent to investors on Friday morning,Benzinga reports. The brokerage currently has an outperform rating on the biotechnology company’s stock. A number of other analysts have also weighed in on the stock. Chardan […] - 2025-08-11 04:50:48
- GSA Capital Partners LLP Grows Stake in REGENXBIO Inc. (NASDAQ:RGNX)
- GSA Capital Partners LLP raised its stake in REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 659.7% during the 1st quarter, HoldingsChannel reports. The firm owned 131,329 shares of the biotechnology company’s stock after acquiring an additional 114,043 shares during the quarter. GSA Capital Partners LLP’s holdings in REGENXBIO were worth $939,000 as of its most […] - 2025-08-01 05:32:51
- REGENXBIO Inc. (NASDAQ:RGNX) Receives $31.63 Average PT from Analysts
- Shares of REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) have earned a consensus rating of “Moderate Buy” from the six research firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price […] - 2025-07-30 04:58:51
- Cerity Partners LLC Acquires New Stake in REGENXBIO Inc. (NASDAQ:RGNX)
- Cerity Partners LLC acquired a new stake in REGENXBIO Inc. (NASDAQ:RGNX – Free Report) during the 1st quarter, Holdings Channel reports. The fund acquired 31,846 shares of the biotechnology company’s stock, valued at approximately $228,000. Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. FNY […] - 2025-07-29 04:17:07
- REGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by Sigma Planning Corp
- Sigma Planning Corp lessened its position in shares of REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 3.9% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 35,860 shares of the biotechnology company’s stock after selling 1,450 shares during the period. Sigma Planning Corp’s holdings in REGENXBIO were worth $256,000 at the end of the […] - 2025-07-22 07:26:52
- Brokerages Set REGENXBIO Inc. (NASDAQ:RGNX) PT at $31.63
- Shares of REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the six analysts that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price […] - 2025-07-03 04:22:55
- Assenagon Asset Management S.A. Has $4.10 Million Stock Position in REGENXBIO Inc. (NASDAQ:RGNX)
- Assenagon Asset Management S.A. lowered its stake in REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 33.1% during the first quarter, HoldingsChannel.com reports. The firm owned 573,173 shares of the biotechnology company’s stock after selling 283,399 shares during the period. Assenagon Asset Management S.A.’s holdings in REGENXBIO were worth $4,098,000 at the end of the most […] - 2025-06-16 05:05:11
- REGENXBIO (NASDAQ:RGNX) Given “Buy” Rating at Chardan Capital
- Chardan Capital reaffirmed their buy rating on shares of REGENXBIO (NASDAQ:RGNX – Free Report) in a research note issued to investors on Monday morning,Benzinga reports. They currently have a $52.00 target price on the biotechnology company’s stock. A number of other brokerages also recently issued reports on RGNX. Wall Street Zen raised REGENXBIO from a […] - 2025-06-10 02:50:56
- REGENXBIO Inc. (NASDAQ:RGNX) Receives Consensus Rating of “Moderate Buy” from Brokerages
- Shares of REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) have been given a consensus rating of “Moderate Buy” by the six analysts that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price objective […] - 2025-06-05 02:48:51
- BNP Paribas Financial Markets Has $743,000 Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX)
- BNP Paribas Financial Markets raised its holdings in REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 370.1% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 96,093 shares of the biotechnology company’s stock after acquiring an additional 75,652 shares during the quarter. BNP Paribas Financial Markets’ […] - 2025-05-23 04:58:51
- REGENXBIO Inc. (NASDAQ:RGNX) Shares Acquired by Jane Street Group LLC
- Jane Street Group LLC grew its stake in REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 325.3% during the fourth quarter, HoldingsChannel reports. The firm owned 164,911 shares of the biotechnology company’s stock after purchasing an additional 126,135 shares during the quarter. Jane Street Group LLC’s holdings in REGENXBIO were worth $1,275,000 as of its most […] - 2025-05-21 04:51:04
- Graham Capital Management L.P. Boosts Stake in REGENXBIO Inc. (NASDAQ:RGNX)
- Graham Capital Management L.P. lifted its position in REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 59.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 28,542 shares of the biotechnology company’s stock after purchasing an additional 10,677 shares during the quarter. Graham Capital Management […] - 2025-05-19 05:27:01
- Critical Analysis: REGENXBIO (NASDAQ:RGNX) versus Novavax (NASDAQ:NVAX)
- REGENXBIO (NASDAQ:RGNX – Get Free Report) and Novavax (NASDAQ:NVAX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitability and earnings. Risk & Volatility REGENXBIO has a beta of 1.11, […] - 2025-05-19 04:42:52
- Tower Research Capital LLC TRC Acquires 10,714 Shares of REGENXBIO Inc. (NASDAQ:RGNX)
- Tower Research Capital LLC TRC increased its holdings in shares of REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 442.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 13,138 shares of the biotechnology company’s stock after acquiring an additional 10,714 shares during the […] - 2025-05-09 05:23:02
- Norges Bank Makes New $3.47 Million Investment in REGENXBIO Inc. (NASDAQ:RGNX)
- Norges Bank purchased a new stake in REGENXBIO Inc. (NASDAQ:RGNX – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 449,400 shares of the biotechnology company’s stock, valued at approximately $3,474,000. Several other institutional investors and hedge funds also recently […] - 2025-04-11 05:13:01
- Mitsubishi UFJ Asset Management Co. Ltd. Has $198,000 Stake in REGENXBIO Inc. (NASDAQ:RGNX)
- Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in shares of REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 48.2% during the 4th quarter, Holdings Channel reports. The institutional investor owned 25,430 shares of the biotechnology company’s stock after buying an additional 8,267 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in […] - 2025-04-04 05:12:56
- EntryPoint Capital LLC Invests $97,000 in REGENXBIO Inc. (NASDAQ:RGNX)
- EntryPoint Capital LLC acquired a new stake in REGENXBIO Inc. (NASDAQ:RGNX – Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 12,538 shares of the biotechnology company’s stock, valued at approximately $97,000. Other large investors have also bought and sold shares […] - 2025-03-31 05:24:54
- REGENXBIO Inc. (NASDAQ:RGNX) Receives $33.88 Average Price Target from Brokerages
- REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seven ratings firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month price […] - 2025-03-25 03:36:46
- AlphaQuest LLC Trims Stake in REGENXBIO Inc. (NASDAQ:RGNX)
- AlphaQuest LLC decreased its position in shares of REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 66.9% during the fourth quarter, Holdings Channel reports. The fund owned 7,959 shares of the biotechnology company’s stock after selling 16,113 shares during the period. AlphaQuest LLC’s holdings in REGENXBIO were worth $62,000 as of its most recent SEC filing. […] - 2025-03-20 06:13:10
- HC Wainwright Issues Pessimistic Forecast for REGENXBIO (NASDAQ:RGNX) Stock Price
- REGENXBIO (NASDAQ:RGNX – Free Report) had its price target cut by HC Wainwright from $36.00 to $34.00 in a research report sent to investors on Monday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. A number of other equities analysts also recently weighed in on RGNX. The Goldman Sachs Group […] - 2025-03-18 03:54:45
- REGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by New York State Common Retirement Fund
- New York State Common Retirement Fund decreased its position in shares of REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 17.4% in the fourth quarter, HoldingsChannel reports. The firm owned 13,746 shares of the biotechnology company’s stock after selling 2,900 shares during the quarter. New York State Common Retirement Fund’s holdings in REGENXBIO were worth $106,000 […] - 2025-03-06 08:19:25
- Brokerages Set REGENXBIO Inc. (NASDAQ:RGNX) Target Price at $33.45
- Shares of REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eleven analysts that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price target […] - 2025-02-28 04:43:06
- REGENXBIO (NASDAQ:RGNX) Stock Rating Upgraded by StockNews.com
- REGENXBIO (NASDAQ:RGNX – Get Free Report) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Tuesday. RGNX has been the topic of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 target price on shares of REGENXBIO […] - 2025-02-27 04:15:04
- StockNews.com Downgrades REGENXBIO (NASDAQ:RGNX) to Sell
- REGENXBIO (NASDAQ:RGNX – Get Free Report) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday. Several other research firms have also issued reports on RGNX. The Goldman Sachs Group lowered shares of REGENXBIO from a “buy” rating to a “neutral” […] - 2025-02-17 04:39:03
- The Goldman Sachs Group Downgrades REGENXBIO (NASDAQ:RGNX) to Neutral
- REGENXBIO (NASDAQ:RGNX – Get Free Report) was downgraded by analysts at The Goldman Sachs Group from a “buy” rating to a “neutral” rating in a report issued on Tuesday, MarketBeat reports. They presently have a $14.00 price objective on the biotechnology company’s stock, down from their prior price objective of $38.00. The Goldman Sachs Group’s […] - 2025-02-13 06:46:49
- Raymond James Initiates Coverage on REGENXBIO (NASDAQ:RGNX)
- Raymond James assumed coverage on shares of REGENXBIO (NASDAQ:RGNX – Free Report) in a research note issued to investors on Friday morning. The firm issued an outperform rating and a $27.00 price target on the biotechnology company’s stock. A number of other analysts have also commented on the company. StockNews.com lowered REGENXBIO from a “hold” […] - 2025-02-10 14:57:04
iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) RGNX holdings
| Date | Number of RGNX Shares Held | Base Market Value of RGNX Shares | Local Market Value of RGNX Shares | Change in RGNX Shares Held | Change in RGNX Base Value | Current Price per RGNX Share Held | Previous Price per RGNX Share Held |
|---|
| 2025-12-03 (Wednesday) | 36,561 | USD 470,906 | USD 470,906 | 0 | USD 24,496 | USD 12.88 | USD 12.21 |
| 2025-12-02 (Tuesday) | 36,561 | USD 446,410 | USD 446,410 | 1,320 | USD 2,373 | USD 12.21 | USD 12.6 |
| 2025-12-01 (Monday) | 35,241 | USD 444,037 | USD 444,037 | 0 | USD -27,840 | USD 12.6 | USD 13.39 |
| 2025-11-28 (Friday) | 35,241 | USD 471,877 | USD 471,877 | 88 | USD 5,748 | USD 13.39 | USD 13.26 |
| 2025-11-27 (Thursday) | 35,153 | USD 466,129 | USD 466,129 | 0 | USD 0 | USD 13.26 | USD 13.26 |
| 2025-11-26 (Wednesday) | 35,153 | USD 466,129 | USD 466,129 | 264 | USD -3,128 | USD 13.26 | USD 13.45 |
| 2025-11-25 (Tuesday) | 34,889 | USD 469,257 | USD 469,257 | 440 | USD 47,946 | USD 13.45 | USD 12.23 |
| 2025-11-24 (Monday) | 34,449 | USD 421,311 | USD 421,311 | 89 | USD 15,863 | USD 12.23 | USD 11.8 |
| 2025-11-21 (Friday) | 34,360 | USD 405,448 | USD 405,448 | 0 | USD 31,955 | USD 11.8 | USD 10.87 |
| 2025-11-20 (Thursday) | 34,360 | USD 373,493 | USD 373,493 | -352 | USD -5,909 | USD 10.87 | USD 10.93 |
| 2025-11-19 (Wednesday) | 34,712 | USD 379,402 | USD 379,402 | 88 | USD -10,118 | USD 10.93 | USD 11.25 |
| 2025-11-18 (Tuesday) | 34,624 | USD 389,520 | USD 389,520 | 528 | USD 9,691 | USD 11.25 | USD 11.14 |
| 2025-11-17 (Monday) | 34,096 | USD 379,829 | USD 379,829 | 176 | USD -10,590 | USD 11.14 | USD 11.51 |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of RGNX by Blackrock for IE00BYXG2H39
Show aggregate share trades of RGNX| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-12-02 | BUY | 1,320 | | | 12.210* | | 9.04 |
| 2025-11-28 | BUY | 88 | | | 13.390* | | 9.00 |
| 2025-11-26 | BUY | 264 | 13.800 | 13.120 | 13.188 | USD 3,482 | 8.96 |
| 2025-11-26 | BUY | 264 | 13.800 | 13.120 | 13.188 | USD 3,482 | 8.96 |
| 2025-11-25 | BUY | 440 | 13.630 | 12.040 | 12.199 | USD 5,368 | 8.94 |
| 2025-11-24 | BUY | 89 | 12.455 | 11.810 | 11.875 | USD 1,057 | 8.92 |
| 2025-11-20 | SELL | -352 | | | 10.870* | | 8.90 Profit of 3,132 on sale |
| 2025-11-19 | BUY | 88 | | | 10.930* | | 8.89 |
| 2025-11-18 | BUY | 528 | | | 11.250* | | 8.88 |
| 2025-11-17 | BUY | 176 | 11.770 | 10.950 | 11.032 | USD 1,942 | 8.87 |
| 2025-11-14 | BUY | 88 | 11.910 | 11.250 | 11.316 | USD 996 | 8.85 |
| 2025-11-12 | BUY | 88 | | | 11.600* | | 8.82 |
| 2025-11-10 | BUY | 87 | 11.810 | 10.860 | 10.955 | USD 953 | 8.80 |
| 2025-11-06 | BUY | 87 | 11.795 | 11.000 | 11.079 | USD 964 | 8.78 |
| 2025-11-04 | BUY | 88 | 11.955 | 11.375 | 11.433 | USD 1,006 | 8.75 |
| 2025-10-30 | BUY | 440 | 13.260 | 12.750 | 12.801 | USD 5,632 | 8.69 |
| 2025-10-29 | BUY | 176 | 12.840 | 13.400 | 13.344 | USD 2,349 | 8.67 |
| 2025-10-22 | SELL | -348 | 12.190 | 12.990 | 12.910 | USD -4,493 | 8.55 Loss of -1,517 on sale |
| 2025-10-20 | BUY | 174 | 12.640 | 12.820 | 12.802 | USD 2,228 | 8.50 |
| 2025-10-17 | BUY | 434 | 11.730 | 12.315 | 12.256 | USD 5,319 | 8.49 |
| 2025-10-15 | BUY | 688 | 12.300 | 12.345 | 12.341 | USD 8,490 | 8.46 |
| 2025-10-03 | BUY | 616 | 10.430 | 10.997 | 10.940 | USD 6,739 | 8.44 |
| 2025-10-02 | BUY | 88 | 10.580 | 10.580 | 10.580 | USD 931 | 8.43 |
| 2025-09-30 | BUY | 176 | 9.650 | 10.005 | 9.970 | USD 1,755 | 8.41 |
| 2025-09-26 | BUY | 176 | 9.650 | 9.670 | 9.668 | USD 1,702 | 8.40 |
| 2025-09-25 | BUY | 176 | 9.360 | 9.730 | 9.693 | USD 1,706 | 8.39 |
| 2025-09-18 | BUY | 90 | 9.360 | 9.483 | 9.471 | USD 852 | 8.38 |
| 2025-09-17 | BUY | 270 | 9.030 | 9.500 | 9.453 | USD 2,552 | 8.37 |
| 2025-08-20 | SELL | -352 | 8.070 | 8.190 | 8.178 | USD -2,879 | 8.37 Profit of 67 on sale |
| 2025-07-30 | BUY | 348 | 8.750 | 9.320 | 9.263 | USD 3,224 | 8.36 |
| 2025-07-17 | SELL | -174 | 8.690 | 8.950 | 8.924 | USD -1,553 | 8.34 Loss of -101 on sale |
| 2025-07-11 | SELL | -704 | 8.680 | 9.110 | 9.067 | USD -6,383 | 8.34 Loss of -514 on sale |
| 2025-07-07 | BUY | 264 | 8.430 | 8.783 | 8.748 | USD 2,309 | 8.32 |
| 2025-07-02 | BUY | 4,840 | 8.620 | 8.790 | 8.773 | USD 42,461 | 8.32 |
| 2025-06-11 | BUY | 178 | 10.200 | 10.636 | 10.592 | USD 1,885 | 8.27 |
| 2025-06-10 | BUY | 178 | 9.810 | 10.131 | 10.099 | USD 1,798 | 8.26 |
| 2025-06-04 | SELL | -89 | 10.080 | 10.580 | 10.530 | USD -937 | 8.22 Loss of -206 on sale |
| 2025-04-23 | BUY | 89 | 8.870 | 9.160 | 9.131 | USD 813 | 7.96 |
| 2025-04-10 | SELL | -712 | 5.410 | 5.773 | 5.737 | USD -4,085 | 8.13 Profit of 1,705 on sale |
| 2025-04-08 | SELL | -89 | 5.310 | 6.270 | 6.174 | USD -549 | 8.19 Profit of 179 on sale |
| 2025-04-07 | SELL | -89 | 5.930 | 6.162 | 6.139 | USD -546 | 8.22 Profit of 185 on sale |
| 2025-04-04 | SELL | -450 | 6.290 | 6.545 | 6.520 | USD -2,934 | 8.24 Profit of 774 on sale |
| 2025-04-01 | BUY | 360 | 6.760 | 7.180 | 7.138 | USD 2,570 | 8.27 |
| 2025-03-31 | SELL | -270 | 7.150 | 7.460 | 7.429 | USD -2,006 | 8.28 Profit of 231 on sale |
| 2025-03-21 | BUY | 3,591 | 8.240 | 8.370 | 8.357 | USD 30,010 | 8.29 |
| 2025-03-14 | SELL | -1,232 | 6.720 | 7.820 | 7.710 | USD -9,499 | 8.34 Profit of 771 on sale |
| 2025-03-07 | SELL | -154 | 6.340 | 6.580 | 6.556 | USD -1,010 | 8.49 Profit of 297 on sale |
| 2025-03-04 | SELL | -77 | 5.920 | 5.970 | 5.965 | USD -459 | 8.60 Profit of 203 on sale |
| 2025-02-25 | BUY | 154 | 6.720 | 6.870 | 6.855 | USD 1,056 | 8.78 |
| 2025-02-19 | SELL | -77 | 7.460 | 7.720 | 7.694 | USD -592 | 8.89 Profit of 92 on sale |
| 2025-02-13 | BUY | 231 | 7.320 | 7.330 | 7.329 | USD 1,693 | 9.01 |
| 2025-02-12 | BUY | 77 | 7.200 | 7.300 | 7.290 | USD 561 | 9.05 |
| 2025-02-11 | BUY | 308 | 7.330 | 7.510 | 7.492 | USD 2,308 | 9.08 |
| 2024-12-30 | SELL | -3,535 | 7.230 | 7.500 | 7.473 | USD -26,417 | 9.61 Profit of 7,554 on sale |
| 2024-11-18 | SELL | -1,290 | 10.150 | 11.380 | 11.257 | USD -14,522 | 9.58 Loss of -2,167 on sale |
| 2024-11-08 | SELL | -86 | 11.160 | 11.700 | 11.646 | USD -1,002 | 9.40 Loss of -193 on sale |
| 2024-10-21 | SELL | -87 | 10.370 | 11.230 | 11.144 | USD -970 | 0.00 Loss of -970 on sale |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of RGNX
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 64,479 | 0 | 139,400 | 46.3% |
| 2025-09-18 | 84,937 | 0 | 121,818 | 69.7% |
| 2025-09-17 | 47,973 | 16 | 100,960 | 47.5% |
| 2025-09-16 | 43,295 | 0 | 70,718 | 61.2% |
| 2025-09-15 | 72,739 | 200 | 159,666 | 45.6% |
| 2025-09-12 | 54,737 | 1,000 | 99,783 | 54.9% |
| 2025-09-11 | 67,337 | 0 | 112,580 | 59.8% |
| 2025-09-10 | 52,185 | 350 | 122,096 | 42.7% |
| 2025-09-09 | 46,876 | 0 | 99,349 | 47.2% |
| 2025-09-08 | 68,417 | 0 | 150,461 | 45.5% |
| 2025-09-05 | 91,648 | 0 | 217,582 | 42.1% |
| 2025-09-04 | 75,373 | 19,896 | 190,431 | 39.6% |
| 2025-09-03 | 156,369 | 0 | 215,631 | 72.5% |
| 2025-09-02 | 57,661 | 3,400 | 134,029 | 43.0% |
| 2025-08-29 | 62,046 | 0 | 130,707 | 47.5% |
| 2025-08-28 | 56,171 | 800 | 186,332 | 30.1% |
| 2025-08-27 | 94,599 | 0 | 211,224 | 44.8% |
| 2025-08-26 | 81,311 | 0 | 229,911 | 35.4% |
| 2025-08-25 | 104,388 | 0 | 361,323 | 28.9% |
| 2025-08-22 | 123,995 | 1,150 | 503,774 | 24.6% |
| 2025-08-21 | 28,093 | 0 | 103,803 | 27.1% |
| 2025-08-20 | 77,529 | 0 | 180,996 | 42.8% |
| 2025-08-19 | 99,073 | 0 | 300,779 | 32.9% |
| 2025-08-18 | 40,585 | 0 | 134,689 | 30.1% |
| 2025-08-15 | 49,186 | 0 | 161,104 | 30.5% |
| 2025-08-14 | 77,737 | 10 | 310,272 | 25.1% |
| 2025-08-13 | 72,888 | 0 | 417,860 | 17.4% |
| 2025-08-12 | 73,440 | 212 | 379,241 | 19.4% |
| 2025-08-11 | 110,252 | 0 | 225,658 | 48.9% |
| 2025-08-08 | 133,652 | 0 | 235,169 | 56.8% |
| 2025-08-07 | 182,763 | 39 | 353,534 | 51.7% |
| 2025-08-06 | 67,867 | 45 | 257,881 | 26.3% |
| 2025-08-05 | 65,463 | 0 | 171,330 | 38.2% |
| 2025-08-04 | 53,346 | 7,900 | 129,540 | 41.2% |
| 2025-08-01 | 69,885 | 696 | 254,539 | 27.5% |
| 2025-07-31 | 45,311 | 511 | 217,767 | 20.8% |
| 2025-07-30 | 110,439 | 0 | 393,789 | 28.0% |
| 2025-07-29 | 48,595 | 0 | 595,404 | 8.2% |
| 2025-07-28 | 56,056 | 234 | 197,594 | 28.4% |
| 2025-07-25 | 101,848 | 0 | 185,552 | 54.9% |
| 2025-07-24 | 75,888 | 0 | 210,767 | 36.0% |
| 2025-07-23 | 138,517 | 0 | 294,989 | 47.0% |
| 2025-07-22 | 72,374 | 0 | 148,798 | 48.6% |
| 2025-07-21 | 118,276 | 891 | 294,218 | 40.2% |
| 2025-07-18 | 112,165 | 0 | 299,884 | 37.4% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Note: All information is provided as is without warranty and should be used for indicative purposes only.
You should independently check data before making any investment decision.
This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.
Copyright Market Footprint Ltd. Privacy Policy